Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465139 | 0.79 | ALDH1A1 (0.48) | CA1CA2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10260605 | 0.79 | CA2 (0.44) | CA1CA2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL37874 | 0.77 | CA2 (0.56) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| SCHEMBL4457449 | 0.77 | CA2 (0.56) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| Hydroxyamine SCHEMBL31697696 | 0.75 | CA2 (0.55) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| SCHEMBL23886640 | 0.74 | CA2 (0.53) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| SCHEMBL6275307 | 0.74 | CA2 (0.53) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| SCHEMBL6897439 | 0.74 | CA2 (0.53) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| Ammonia Solution, Strong SCHEMBL1583080 | 0.74 | CA2 (0.53) | CA1CA2MAPK1SMN1; SMN2PTPN1 | |
| SCHEMBL6897756 | 0.74 | CA2 (0.53) | CA1CA2MAPK1SMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178411-A1 | Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-08-10 | — | — | US | disclosed |
| WO-2005003081-A2 | SULFONIMIDE CONTAINING COMPOUNDS AND THEIR USE IN POLYMER ELECTROLYTE MEMBRANES FOR ELECTROCHEMICAL CELLS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178411-A1 | Sulfonimide containing compounds and their use in polymer electrolyte membranes for electrochemical cells | HCN2, KCNN2, NHERF1 | CA1 22/4885CA2 12/4885MAPK1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.